XML 36 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill and Intangible Assets (Tables)
9 Months Ended
Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary of intangible assets by major asset class
The following sets forth the goodwill and intangible assets by major asset class:
 
 
 
 
September 30, 2018
 
December 31, 2017
 
Useful
Life
(Yrs)
Gross
 
Accumulated
Amortization
 
Net Book
Value
 
Gross
 
Accumulated
Amortization
 
Net Book
Value
Indefinite lived:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill(a)
 
 
$
10,513,371

 
$

 
$
10,513,371

 
$
10,513,371

 
$

 
$
10,513,371

Definite lived:
 
 
 
 
 
 
 
 
 
 
 
 
 
Patents
8 – 17
 
5,802,528

 
(5,726,978
)
 
75,550

 
5,802,528

 
(5,681,673
)
 
120,855

Licenses
8 – 17
 
1,323,761

 
(1,212,170
)
 
111,591

 
1,323,761

 
(1,190,609
)
 
133,152

CELLECTRA®(b)
5 – 11
 
8,106,270

 
(7,572,419
)
 
533,851

 
8,106,270

 
(7,252,108
)
 
854,162

GHRH(b)
11
 
335,314

 
(295,709
)
 
39,605

 
335,314

 
(271,948
)
 
63,366

Bioject(c)
2 – 15
 
5,100,000

 
(1,808,889
)
 
3,291,111

 
5,100,000

 
(1,405,556
)
 
3,694,444

Other(d)
18
 
4,050,000

 
(3,075,000
)
 
975,000

 
4,050,000

 
(2,906,250
)
 
1,143,750

Total intangible assets
 
 
24,717,873

 
(19,691,165
)
 
5,026,708

 
24,717,873

 
(18,708,144
)
 
6,009,729

Total goodwill and intangible assets
 
 
$
35,231,244

 
$
(19,691,165
)
 
$
15,540,079

 
$
35,231,244

 
$
(18,708,144
)
 
$
16,523,100


(a)
Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for $3.9 million, $6.2 million and $400,000, respectively.
(b)
CELLECTRA® and GHRH are developed technologies which were recorded from the acquisition of VGX.
(c)
Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.
(d)
Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.